Mark your calendars for the 19th annual BIDMC Cancer Center Symposium! 🗓️ Friday, November 20th, 2026 ⏲️ 9 AM - 5 PM 📍 Joseph B. Martin Conference Center 🎟️ Free registration Register today➡️ bit.ly/CCSymposium26 #CancerSymposium

🧬 #CancerResearch spotlight: Annalisa Di Ruscio, MD, PhD with colleagues from BIDMC and other institutions demonstrate how an RNA-mediated mechanism controls the initiation of DNA replication. The findings may have therapeutic potential for diseases involving abnormal DNA replication. 📝 @nature.com

🎉 Congratulations to our very own Dr. Ann Kim for graduating from the @ash.hematology.org Hematology-Focused Fellowship Training Program (HFFTP)! We're proud to celebrate this important milestone and look forward to Dr. Kim's continued contributions to the future of #hematology.

📷 @alextoker.bsky.social, co-organizer for @faseborg.bsky.social "Cell Signaling in Cancer" joins members of his lab at this year's conference. The Toker lab presented a range of new scientific discoveries. And shout out to @piskounovalab.bsky.social for helping co-organize this year's event!

⭐️ Congrats to Jan Heng, PhD for receiving a Frontiers Program Award from the Massachusetts Life Sciences Center! Her research will investigate how estrogen therapy alters the mechanisms of #breastcancer and #prostatecancer development in individuals carrying BRCA2.

🩸 Can you predict venous thromboembolism (VTE) in a patient with cancer before a blood clot forms? Researchers at BIDMC like @ioavlachos.bsky.social and collaborators used plasma proteomics to develop a predictive model for VTE and uncovered IL-17 as a potential therapeutic target. 📝 @science.org

❔ How is #cervicalcancer care evolving? 🎙️ Dr. Meghan Shea, medical oncologist and disease program leader at BIDMC joins Ursula Matulonis, MD @danafarber.bsky.social on @onclive.bsky.social to discuss advances in cervical cancer treatments like immunotherapy and ADCs. Listen➡️ bit.ly/4vQcQ6f

❓ Do all BRCA1-mutant tumors develop the same way? Namrata Nilavar, PhD, Postdoc Fellow, BIDMC, presented her research at the 2026 @acscan.bsky.social Breakfast in Boston. Her work suggests distinct BRCA1 mutations may drive different patterns of genomic instability and tumor growth. #CancerResearch

Live from our Cancer Research Institute seminar series: Shomit Sengupta, PhD; VP, Biology at Atavistik Bio. Sengupta leads efforts to identify novel targets for rare metabolic and hematology diseases, leveraging nutrient-sensing for drug discovery. #CancerResearch #BioTech

🧬 Nadine Tung, MD moderated a cancer genetics session #ASCO26. Key takeaways: • Some BRCA2 variants may affect #prostatecancer outcomes • Prostate cancer genetic risk assessment is evolving • PSA + MRI help prostate cancer detection in men w/BRCA2 • The role of GLP-1s in cancer prevention is unclear

❔ Why might immunotherapy work well for one patient but not another with the same cancer? 💡 Dr. Bockorny, GI medical oncologist at BIDMC, highlights how a chromatin regulator mutation (KMT2C) could serve as a predictive biomarker and inform who will respond to immunotherapy in GI cancers #ASCO26

📸 Cancer Research Institute seminar recap: Shengfang Jin, PhD, President and CEO, ENSEM Therapeutics — “ETX-636, a Next-Generation Allosteric Pan-Mutant-Selective PI3Kα Dual Inhibitor and Degrader for the Treatment of PIK3CA-Mutant Diseases.” #CancerResearch #PrecisionMedicine #ComputationalBiology

⌛️ We are two days away from #ASCO26! From translational science to clinical advances, BIDMC oncologists are presenting new research at the @ascocancer.bsky.social annual meeting that will help shape the future of cancer care. We'll see you in Chicago!

📸 #AUA26 photos! Our team presented a wide range of research: 💡 Prediction of #bladdercancer recurrence: SEER-Medicare analysis 💡 Baseline frailty, treatment intensity, and clinical outcomes in older adults with #prostatecancer 💡 #AI scribes and reduction of clerical burden

⭐️ This #NursesWeek, we recognize our recipients of this year's Excellence in Hematology/Oncology Nursing Award. Congratulations, Siobhan and Bridget, on this outstanding achievement! ❤️ We thank all of our oncology nurses for their commitment to delivering extraordinary care.

Live from our Cancer Research Institute seminar series: Sabrina Spencer, PhD @colorado.edu. Her lab pioneered the usage of live-cell time-lapse microscopy and fluorescent biosensors to study rapid, non-genetic drug adaptation in MAPK and cell cycle signaling. #CancerResearch #CancerBiology

At BIDMC, we offer a minimally invasive surgical procedure for patients with #testicularcancer. This robotic surgical approach can shorten recovery times and for some patients, cure them of disease. Learn more ➡️ bit.ly/4sWYsHp #TesticularCancerAwarenessMonth

♥️For patients with underlying cardiovascular disease, especially older adults, some cancer therapies can affect #hearthealth. Dr. Aarti Asnani, BIDMC explains how cardio-oncology helps monitor and protect patients with cancer throughout treatment so care can continue safely.

Thanks to our speakers, moderators, poster judges, event staff, and attendees for making #RNAMedicine2026 such a success! Your support will advance novel discoveries in #RNA science for years to come. @bartellab.bsky.social @raflynn5.bsky.social @piskounovalab.bsky.social @steitzlab.bsky.social

🏆 Congratulations to our #RNAMedicine2026 poster award winners for their extraordinary research! ⭐️ Mahima Dewani, PhD @harvardmed.bsky.social: Translational Science ⭐️ Marsel Lino, PhD: Basic Science ⭐️ Michelle Luo: Basic Science ⭐️ @pouryany.bsky.social: Collaborative Science

We’re honored to recognize Joan Steitz, PhD, with our #RNAMedicine2026 Lifetime Achievement award. In 1979, Steitz & colleagues described snRNPs, a breakthrough in understanding how #RNA is spliced. She’s a pioneering woman in science who has been awarded 21 honorary degrees. @steitzlab.bsky.social

📸 Live from #RNAMedicine2026: Over 40 posters are on-display ranging from basic, translational, and collaborative #RNA science. We are excited to showcase groundbreaking research and scientists from across the region!

“Your work in #RNA medicine is shaping the future of healthcare, and this work must endure.” George Daley, MD, PhD, Dean @harvardmed.bsky.social Special thanks to Vikram Deshpande, MD and Frank Slack, PhD for delivering opening remarks at #RNAMedicine2026.

#AACR26 spotlight: Carlota Pages-Geli, PhD, “Unbiased discovery of novel microphage-activating immunotherapies for ALK+ #NSCLC.” 💡Combining CD47xTROP2 bispecific antibodies with lorlatinib produced synergistic anti-tumor effects — a promising strategy to overcome drug resistance. #LungCancer

#CancerResearch Spotlight - Tina Yi-Jin Hsieh, MD, BIDMC: "GLP-1 RAs are associated with a lower risk for hysterectomy in endometrial intraepithelial neoplasia/early-stage #endometrialcancer when added to standard progestin therapy." ➡️Learn More: bit.ly/4chN0kH 📰 @medscape.com

Live from our Cancer Research Institute seminar: Frank Borriello, MD, PhD, Founder & CEO of Alloplex Biotherapeutics, joins us for an oncology industry lecture. He highlights their ENLIST immune cell training platform for manufacturing adoptive cell therapies. #CancerResearch #PrecisionMedicine

#CancerResearch Spotlight: Senior author Mandeep Sawhney, MD, BIDMC Division of Gastroenterology, and team found patients prefer EUS for #pancreaticcancer screening, and MRCP for pancreatic cyst surveillance. These findings support a more patient-centered, individualized screening approach.

📸 #SGO2026 Spotlights! ⭐️Tina Yi Jin Hsieh, MD, MPH, MS presentation: Impact of GLP-1RA plus Progestin Therapy on Fertility-Sparing Management of Endometrial Intraepithelial Neoplasia and #EndometrialCancer ⭐️Linh Nguyen, MD poster: Quality of Care, Survival, Financial Toxicity in #OvarianCancer

🧬The @tarumuranen.bsky.social lab identified an ECM-induced DNA repair pathway - NDRG1+TGM2. This pathway helps regulate DNA replication fork stability and drives a stress-responsive mechanism that supports replication homeostasis in cancer cells. 📝 @aacrjournals.bsky.social #CancerResearch

Live from our Cancer Research Institute seminar: Vinod Balachandran, MD @mskcancercenter.bsky.social. Using reverse translation to uncover a biological basis of exceptional response in #PancreaticCancer survivors, his lab identifies mechanisms in model systems and accelerate new immunotherapies.